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1021-9498/Copyright © 2014, Food and Drug Adimplementing effective risk management and assessmentefficiency, the reporting network was subsequently centralized
to establish the National Adverse Drug/Device Reaction (ADR)Reporting Center in 2005. In the same year, an online reportingThe Taiwan Food and Drug Administration, Ministry of Health
and Welfare (hereinafter referred to as the “TFDA”) ensures
consistentand improvedmanagementofmedicaldevicesafety.
Medical devices usually refer to any equipment, software, or
material intended to be used in the diagnosis, prevention,
monitoring, or treatment of diseases or injuries [1]. Because of
the increasing complexity ofmedical devices and thevariability
of usage environments, the concept of “total product life cycle”
has been introducedduring the product development phase [2].
Besides the strict regulatory framework to ensure the safety of
both patients and health care providers, sustained monitoring
and information collection are also crucial tasks to evaluate the
safety and risk of marketed medical devices. Postmarket sur-
veillance of medical devices includes reporting of adverse re-
actions and obligatory periodic safety update report for high-
risk medical devices in the monitoring stage. All the current
efforts on postmarket surveillance in Taiwan are aimed atinistration, Ministry of He
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ministration, Taiwan. Publs
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thicontrols and improving the protection for our citizens.
Two online reporting systems are being established for
sustained monitoring and collecting the safety information on
marketed medical devices, namely, Adverse Events of Medical
Device Reporting System and Defective Product Reporting
System. In 1988, a nationwide reporting systemof adverse drug
reaction was set up. This network included one national center
and four regional centers located in northern, central, south-
ern, and eastern Taiwan. In 2001, the Adverse Events ofMedical
Device Reporting System was integrated into this system. To
further harmonize data processing and enhance operational
ystem for medical product defect was also established. The
efects may be attributed to manufacture, transportation,
torage, distribution, and/or handling of the product, with the
istinction that a product defect may or may not result in an
dverse event (e.g., improper labeling). For the purpose of
nsuring the quality of medical devices and preventing end
sers frompossible hazards, voluntary reporting is encouraged
hen a product defect is found prior to use.
Reports on adverse events of medical devices or defective
roducts are routinely collected from all the regions of Taiwan
aily. Manufacturers, licensed agents, health care providers,
r end users all can report problems related to the medical
evices freely through the website. The total numbers of both
dverse events and defective product reporting from 2003 to
013 are indicated in Fig. 1. The steady increasing trend of
dverse events reporting with the passing years may be
elated to the increasing complexity of medical devices and
e variability of usage environments. The numbers ofalth and Welfare, No. 161-2, Kunyang St., Nangang District, Taipei
shed by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
Fig. 1 e Reporting numbers of adverse events (open bars) and defective products (closed bars) for the period between 2003
and 2013.
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growth since 2010. This result implied that the continual
promotion and education could be an efficient way to
encourage voluntary reporting of defective products.
All the reports of adverse event or product problem were
first registered into the database of the National ADR Reporting
Center, which is operated under the Taiwan Drug Relief
Foundation. National Taiwan University, the TFDA's commis-
sioned agency, would subsequently review and preliminarily
evaluate the safety data. As an example, 144 adverse event
reports for medical devices were received in 2013. Of the 106
reports that have been evaluated currently, about 8.7% (9 re-
ports) were “severe” adverse events and 81.5% percent (84 re-
ports) were “moderate/mild” adverse events. Furthermore,
1481 valid defective product reports received from January 1,
2013, to October 31, 2013, were classified and assessed ac-
cording to the Device Problem Code [3]. The five most common
types of device defects were “1250: Fluid Leak” (214 reports,
12.7%), “2944: Foreign Material Present in Device” (210 reports,
12.4%), “2588: Defective Item” (150 reports, 8.9%), “1506: Product
Quality Issue” (125 reports, 7.4%), and “1104: Detachment of
Device Component” (121 reports, 7.2%). Further findings indi-
cated that disposable products, such as administration set,
syringe, gauze/sponge, and absorbent fiber, were the most
commonly reported cases. These results indicated that the
reporting tendency with regard to defective products would be
strongly dependent on the usage frequency of the products and
also on the specific characteristics of the device defects.
The proper measures undertaken are notifying the manu-
facturer to take appropriate action, such as product correction,
sales restriction, or market withdrawal, and also performing
audit inspection. The Safety Evaluation Advisory Committee,
which consists of 15 panelists including scientific, engineering,
and clinical experts, will also propose recommendations for
the TFDA to consider possible regulatory action.
The TFDA actively and routinely monitors overseas infor-
mation related tomedical device alert and recall fromwebsites
of foreign competent authority, such as the FDA, theMedicines
and Healthcare products Regulatory Agency (UK), the Bunde-
sinstitut fu¨r Arzneimittel und Medizinprodukte (Federal Insti-
tute for Drugs andMedical Devices; Germany), the Swissmedic,
the Health Canada, the Therapeutic Goods Administration(Australia), and the Pharmaceuticals Medical Devices Agency
(Japan), to respond accordingly and promptly. Furthermore,
cooperative agreements with the United States, European
Union, Switzerland, Australia, and Liechtenstein have been
established since 1998. Such international cooperation helps to
mutually exchange medical device vigilance reports and audit
reports. Furthermore, the TFDA has also applied to join the
Safety Alert Dissemination System of Asian Harmonization
WorkingParty in2010. Theagency receiveda total of 5619safety
alerts, recall notices, or any issues of concern (both domestic
and international) between 2010 and 2012. Of these, 580 reports
were translated and disseminated. In addition, with participa-
tion in the global National Competent Authority Report (NCAR)
program in 2010, the TFDA could further exchange information
related to recall notifications, safety alerts, hazard alerts,
product notifications, and other product advisories. Up to
December 2013, 1047 reports on defective medical devices and
recall notices have been received from the NCAR Secretariat.
Bearing the responsibility as a gatekeeper of the quality of
medical devices, the TFDA will unceasingly work hard on
improving all kinds of measures to provide our citizens with a
better quality of life.Conflicts of interest
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